Danish allergy company ALK-Abelló has signed a strategic partnership with Chinese biopharmaceutical firm GenSci to develop and commercialise its house dust mite allergy immunotherapy (AIT) products in China.
Under the agreement, GenSci gains exclusive rights to ALK’s products Alutard® and ACARIZAX® until the end of 2039. GenSci will take responsibility for sales, marketing, and most clinical development and registration costs, while ALK will continue to handle production and supply.
ALK will receive an upfront payment of around DKK 245 million and is eligible for milestone payments of up to DKK 1.3 billion in total. While the partnership is not expected to materially affect ALK’s 2025 earnings, it is projected to strengthen margins in the medium term.
“We’re very excited about the prospects of speeding up market uptake of ALK’s evidence-based AIT products in China. We see a strong strategic fit and look forward to cooperating with GenSci, which has a well-proven track record in this important market,” says ALK CEO Peter Halling.
China has the world’s largest population suffering from house dust mite allergy, yet fewer than one million people are currently treated with AIT. Through the new partnership, ALK and GenSci aim to expand market penetration by investing in awareness campaigns, hospital collaborations, and digital healthcare initiatives.
Source: BioSpace
